IL12-silenced autologous dendritic cell therapy (Medistem/Benitec)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL12-silenced autologous dendritic cell therapy (Medistem/Benitec)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionInterleukin-12 inhibitors
TargetsInterleukin-12
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedistem Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedistem Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A